Sanofi, Enteris sign agreement for oral diabetes therapies

Enteris BioPharma, Inc., announced it has signed an agreement with Sanofi in order to conduct a research by using Peptelligence, Enteris’ platform, to deliver oral peptides and small molecules. The agreement is aimed at developing an oral formulation of one of Sanofi’s peptides currently in the preclinical stage. Specifically, the product is intended for the treatment of type 2 diabetes.
(Source Enteris press release)